alemtuzumab

常见例句

Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.
阿仑单抗组有2例而抗胸腺细胞球蛋白组有3例发生排斥反应.
Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
阿仑单抗是一种针对T、B细胞的单克隆抗体。
BACKGROUND.: An increase in the incidence of autoimmune diseases has been described in patients receiing alemtuzumab.
背景：接受阿仑单抗免疫诱导治疗治疗患者的自身免疫性疾病发生率增加。
One-year cumulatie graft surial was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group.
1年累积生存率阿仑单抗组为85.;7%25;抗胸腺细胞球蛋白组为87
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单抗;一种人源性抗-CD52抗体;在免疫耐受诱导方案中效果显著;需要最少的免疫抑制维持药物.
CONCLUSIONS.: In this retrospectie analysis, induction with alemtuzumab did not increase the rate of re-emergence of autoantibodies or biopsy-proen recurrence of glomerular disease.
结论：在这项回顾性研究分析中，阿仑单抗免疫诱导并不会增加自身抗体的再次出现率或者活组织检查肾小球疾病的复发率。